Cell Design Labs, Inc.

Precigen, Inc.

Kite Pharma, Inc.

Peter Emtage

Rutul R Shah

Ramya Yarlagadda

Stephen Santoro

Anselm Levskaya

Scott Coyle

Amy E Gilbert

Gabrielle Romain

Spencer Scott

Sarah Wyman

Vladimir Anatolievich Slepushkin

Levi Rupp

Rosa Vincent

Tim Chan

Stephanie Secrest

The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.

Methods and compositions for reducing the immunogenicity of chimeric notch receptors

Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.

Chimeric transmembrane proteins and uses thereof

Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.

Expression of novel cell tags

Provided herein are engineered receptors involved in cytokine signaling. Also provided herein are engineered receptors for modulating TGF-β signaling, methods of modulating TGF-β signaling and treating cancer using chimeric antigen receptors.

TGF-beta receptors and methods of use

Provided herein are chimeric antigen receptors that binds specifically to B-cell maturation antigen (BCMA) and CD307e, nucleic acids that encode these chimeric antigen receptors, and methods of making and using these chimeric antigen receptors.

Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.

Chimeric polypeptides and methods of altering the membrane localization of the same

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

CD33 specific chimeric antigen receptors

Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.

Growing community of inventors

Lafayette, CA, United States of America

Peter Emtage